Clinical Trials Logo
  1. Home
  2. Acquired Hemophilia A
  3. NCT06461533

A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A

Acquired Hemophilia A Clinical Trial

Official title:
General Use-results Survey of OBIZER for I.V. Injection (All-case Surveillance)

Clinical Trial Summary

This study is a survey in Japan of Susoctocog Alfa (Genetical Recombination) intravenous injection used to treat participants with bleeding events of acquired Haemophilia A (AHA). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related from Susoctocog Alfa (Genetical Recombination) intravenous injection and to check if Susoctocog Alfa (Genetical Recombination) intravenous injection improves bleeding events of AHA. During the study, participants with AHA will take Susoctocog Alfa (Genetical Recombination) intravenous injection according to their clinic's standard practice. The study doctors will check for side effects from Susoctocog Alfa (Genetical Recombination) intravenous injection for up to 90 days after the last dose of study drug or until discontinued (varied from participant to participant).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06461533
Study type Observational
Source Takeda
Contact Takeda Contact
Phone +1-877-825-3327
Email medinfoUS@takeda.com
Status Recruiting
Phase
Start date June 10, 2024
Completion date October 31, 2029
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03700229 - Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A Phase 2
Completed NCT04580407 - Study of TAK-672 in Participants With Acquired Hemophilia A Phase 2/Phase 3
Completed NCT01178294 - Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A Phase 2/Phase 3
Completed NCT02610127 - Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
Completed NCT03384277 - Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab Phase 4
Completed NCT03199794 - Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice
Recruiting NCT05345197 - Emicizumab in Patients With Acquired Hemophilia A Phase 2
No longer available NCT01968655 - Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies